Rhythm Pharmaceuticals (RYTM)
(Real Time Quote from BATS)
$38.34 USD
+0.19 (0.50%)
Updated Apr 26, 2024 09:32 AM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
RYTM 38.34 +0.19(0.50%)
Will RYTM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RYTM
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline
Rhythm Pharmaceuticals, Inc. (RYTM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?
Other News for RYTM
Analyst Expectations For Rhythm Pharmaceuticals's Future
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Rhythm Pharmaceuticals (RYTM) and Dexcom (DXCM)
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Commit To Purchase Rhythm Pharmaceuticals At $25, Earn 8.6% Annualized Using Options
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson